CN1143858C - 6,9-二取代的2-[反-(氨基环己基)氨基]嘌呤,其组合物和用途 - Google Patents
6,9-二取代的2-[反-(氨基环己基)氨基]嘌呤,其组合物和用途 Download PDFInfo
- Publication number
- CN1143858C CN1143858C CNB998033979A CN99803397A CN1143858C CN 1143858 C CN1143858 C CN 1143858C CN B998033979 A CNB998033979 A CN B998033979A CN 99803397 A CN99803397 A CN 99803397A CN 1143858 C CN1143858 C CN 1143858C
- Authority
- CN
- China
- Prior art keywords
- amino
- group
- following group
- trans
- aminocyclohexyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines Chemical class 0.000 title claims abstract description 241
- 150000001875 compounds Chemical class 0.000 claims abstract description 151
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 130
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 34
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 230000006907 apoptotic process Effects 0.000 claims abstract description 17
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 150000003053 piperidines Chemical class 0.000 claims description 636
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 620
- XDKPTYKTFBDFFM-UHFFFAOYSA-N 9-cyclopentylpurine Chemical compound C1CCCC1N1C2=NC=NC=C2N=C1 XDKPTYKTFBDFFM-UHFFFAOYSA-N 0.000 claims description 604
- 239000001257 hydrogen Substances 0.000 claims description 120
- 229910052739 hydrogen Inorganic materials 0.000 claims description 120
- 238000002360 preparation method Methods 0.000 claims description 117
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 99
- 210000004027 cell Anatomy 0.000 claims description 98
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 86
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 82
- 229940073608 benzyl chloride Drugs 0.000 claims description 71
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 66
- 229910052736 halogen Inorganic materials 0.000 claims description 63
- 150000002367 halogens Chemical class 0.000 claims description 63
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 63
- 201000011510 cancer Diseases 0.000 claims description 62
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 61
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 54
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 150000002431 hydrogen Chemical class 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 32
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 21
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- GQGAOOHHHZLIMM-UHFFFAOYSA-N 7h-purine;dihydrochloride Chemical compound Cl.Cl.C1=NC=C2NC=NC2=N1 GQGAOOHHHZLIMM-UHFFFAOYSA-N 0.000 claims description 18
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 18
- 210000004907 gland Anatomy 0.000 claims description 16
- 201000001441 melanoma Diseases 0.000 claims description 15
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 14
- 208000032839 leukemia Diseases 0.000 claims description 13
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 12
- 230000006378 damage Effects 0.000 claims description 11
- 230000002062 proliferating effect Effects 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 210000001072 colon Anatomy 0.000 claims description 9
- 239000011630 iodine Substances 0.000 claims description 9
- 229910052740 iodine Inorganic materials 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 210000004072 lung Anatomy 0.000 claims description 8
- 210000005075 mammary gland Anatomy 0.000 claims description 8
- CPHXLFKIUVVIOQ-UHFFFAOYSA-N 2-(trifluoromethoxy)benzaldehyde Chemical group FC(F)(F)OC1=CC=CC=C1C=O CPHXLFKIUVVIOQ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 210000002307 prostate Anatomy 0.000 claims description 7
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 230000019581 neuron apoptotic process Effects 0.000 claims description 5
- 210000000813 small intestine Anatomy 0.000 claims description 5
- 206010024612 Lipoma Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 229940034982 antineoplastic agent Drugs 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000024207 chronic leukemia Diseases 0.000 claims description 3
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 3
- 206010055031 vascular neoplasm Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 201000003076 Angiosarcoma Diseases 0.000 claims description 2
- LCYZTMJGZOGMFI-MXPSUWBQSA-N Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(NNc2c(Cl)cccc2Cl)c2ncn(C3CCCC3)c2n1 Chemical group Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(NNc2c(Cl)cccc2Cl)c2ncn(C3CCCC3)c2n1 LCYZTMJGZOGMFI-MXPSUWBQSA-N 0.000 claims description 2
- AVADVHHRYCGIMB-BCHJJPDRSA-N Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(NNc2ccccc2F)c2ncn(C3CCCC3)c2n1 Chemical compound Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(NNc2ccccc2F)c2ncn(C3CCCC3)c2n1 AVADVHHRYCGIMB-BCHJJPDRSA-N 0.000 claims description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 208000008798 osteoma Diseases 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims 31
- 210000003238 esophagus Anatomy 0.000 claims 2
- 230000000324 neuroprotective effect Effects 0.000 claims 2
- DEVFVVLSBJSUNB-UHFFFAOYSA-N 7h-purine;hydrochloride Chemical compound Cl.N1=CNC2=NC=NC2=C1 DEVFVVLSBJSUNB-UHFFFAOYSA-N 0.000 claims 1
- DWCUFHSZFVHEQY-MCXZQIONSA-N Cl.Cl.CCCCCCCCCCCCNc1nc(N[C@H]2CC[C@H](N)CC2)nc2n(cnc12)C1CCCC1 Chemical group Cl.Cl.CCCCCCCCCCCCNc1nc(N[C@H]2CC[C@H](N)CC2)nc2n(cnc12)C1CCCC1 DWCUFHSZFVHEQY-MCXZQIONSA-N 0.000 claims 1
- ACCJAOARGXHKGH-BCHJJPDRSA-N Cl.Cl.COCCCNc1nc(N[C@H]2CC[C@H](N)CC2)nc2n(cnc12)C1CCCC1 Chemical compound Cl.Cl.COCCCNc1nc(N[C@H]2CC[C@H](N)CC2)nc2n(cnc12)C1CCCC1 ACCJAOARGXHKGH-BCHJJPDRSA-N 0.000 claims 1
- FHABNANYALULNA-MXPSUWBQSA-N Cl.Cl.COCCNc1nc(N[C@H]2CC[C@H](N)CC2)nc2n(cnc12)C1CCCC1 Chemical group Cl.Cl.COCCNc1nc(N[C@H]2CC[C@H](N)CC2)nc2n(cnc12)C1CCCC1 FHABNANYALULNA-MXPSUWBQSA-N 0.000 claims 1
- FMOANJRWZHUWRK-PMXFUEHMSA-N Cl.Cl.COc1cc(CNc2nc(N[C@H]3CC[C@H](N)CC3)nc3n(cnc23)C2CCCC2)cc(OC)c1OC Chemical group Cl.Cl.COc1cc(CNc2nc(N[C@H]3CC[C@H](N)CC3)nc3n(cnc23)C2CCCC2)cc(OC)c1OC FMOANJRWZHUWRK-PMXFUEHMSA-N 0.000 claims 1
- AVWCBSJXHRUFMY-DKAXCJEDSA-N Cl.Cl.Cl.C1C[C@@H](N)CC[C@@H]1NC1=NC(NN2CCC(CC=3C4=CC=CC=C4C=CC=3)CC2)=C(N=CN2C3CCCC3)C2=N1 Chemical compound Cl.Cl.Cl.C1C[C@@H](N)CC[C@@H]1NC1=NC(NN2CCC(CC=3C4=CC=CC=C4C=CC=3)CC2)=C(N=CN2C3CCCC3)C2=N1 AVWCBSJXHRUFMY-DKAXCJEDSA-N 0.000 claims 1
- BLFDNACJPXRGOX-KZLXYENISA-N Cl.Cl.Cl.C1C[C@@H](N)CC[C@@H]1NC1=NC(NN2CCC(CC=3C=C4C=CC=CC4=CC=3)CC2)=C(N=CN2C3CCCC3)C2=N1 Chemical group Cl.Cl.Cl.C1C[C@@H](N)CC[C@@H]1NC1=NC(NN2CCC(CC=3C=C4C=CC=CC4=CC=3)CC2)=C(N=CN2C3CCCC3)C2=N1 BLFDNACJPXRGOX-KZLXYENISA-N 0.000 claims 1
- RJFDSLWYTXDUBQ-HJNPFAAISA-N Cl.Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(NCCNc2ccccc2)c2ncn(C3CCCC3)c2n1 Chemical compound Cl.Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(NCCNc2ccccc2)c2ncn(C3CCCC3)c2n1 RJFDSLWYTXDUBQ-HJNPFAAISA-N 0.000 claims 1
- WPWPEGCTMKNYGH-BCHJJPDRSA-N Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(NCCOCCO)c2ncn(C3CCCC3)c2n1 Chemical group Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(NCCOCCO)c2ncn(C3CCCC3)c2n1 WPWPEGCTMKNYGH-BCHJJPDRSA-N 0.000 claims 1
- WTTIXXMYHRWJMI-BCHJJPDRSA-N Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(NNc2ccc(Cl)cc2Cl)c2ncn(C3CCCC3)c2n1 Chemical compound Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(NNc2ccc(Cl)cc2Cl)c2ncn(C3CCCC3)c2n1 WTTIXXMYHRWJMI-BCHJJPDRSA-N 0.000 claims 1
- YXWOIGADNRUQHU-BCHJJPDRSA-N Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(NNc2ccccc2Cl)c2ncn(C3CCCC3)c2n1 Chemical compound Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(NNc2ccccc2Cl)c2ncn(C3CCCC3)c2n1 YXWOIGADNRUQHU-BCHJJPDRSA-N 0.000 claims 1
- KOCSXSGKVSUPDL-HLDGVKIBSA-N Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(Nc2cccc(F)c2)c2ncn(C3CCCC3)c2n1 Chemical group Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(Nc2cccc(F)c2)c2ncn(C3CCCC3)c2n1 KOCSXSGKVSUPDL-HLDGVKIBSA-N 0.000 claims 1
- DPFVYCFVGBIRHL-HEOZJBRKSA-N Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(Nc2ccccc2)c2ncn(C3CCCC3)c2n1 Chemical group Cl.Cl.N[C@H]1CC[C@@H](CC1)Nc1nc(Nc2ccccc2)c2ncn(C3CCCC3)c2n1 DPFVYCFVGBIRHL-HEOZJBRKSA-N 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000006431 amelanotic melanoma Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 230000000684 melanotic effect Effects 0.000 claims 1
- 210000002394 ovarian follicle Anatomy 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 208
- 210000002569 neuron Anatomy 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract description 3
- 108091007914 CDKs Proteins 0.000 abstract description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 4
- 230000006369 cell cycle progression Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 description 500
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 345
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 184
- UZFVWQZHQDVFRV-UHFFFAOYSA-N 2-chloro-9-cyclopentylpurine Chemical class C12=NC(Cl)=NC=C2N=CN1C1CCCC1 UZFVWQZHQDVFRV-UHFFFAOYSA-N 0.000 description 127
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 95
- KCDIWATZOVCVKI-UHFFFAOYSA-N piperidin-4-ylurea Chemical compound NC(=O)NC1CCNCC1 KCDIWATZOVCVKI-UHFFFAOYSA-N 0.000 description 91
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 88
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 71
- ZTRPYTHOEREHEN-UHFFFAOYSA-N piperazine pyridine Chemical compound N1CCNCC1.N1=CC=CC=C1.N1=CC=CC=C1 ZTRPYTHOEREHEN-UHFFFAOYSA-N 0.000 description 51
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 44
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 37
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 36
- 125000005936 piperidyl group Chemical group 0.000 description 30
- 108050006400 Cyclin Proteins 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 102000016736 Cyclin Human genes 0.000 description 27
- 108010042653 IgA receptor Proteins 0.000 description 25
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 25
- 230000000737 periodic effect Effects 0.000 description 24
- 230000026731 phosphorylation Effects 0.000 description 24
- 238000006366 phosphorylation reaction Methods 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 108091000080 Phosphotransferase Proteins 0.000 description 18
- 230000000394 mitotic effect Effects 0.000 description 18
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 18
- 102000020233 phosphotransferase Human genes 0.000 description 18
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 16
- 239000001301 oxygen Substances 0.000 description 16
- 229910052760 oxygen Inorganic materials 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 230000008859 change Effects 0.000 description 15
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 15
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 230000022131 cell cycle Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 206010006187 Breast cancer Diseases 0.000 description 12
- 208000026310 Breast neoplasm Diseases 0.000 description 12
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 206010025323 Lymphomas Diseases 0.000 description 11
- 230000018199 S phase Effects 0.000 description 11
- 206010041823 squamous cell carcinoma Diseases 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 230000001613 neoplastic effect Effects 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 102000001253 Protein Kinase Human genes 0.000 description 9
- 229940041181 antineoplastic drug Drugs 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 9
- 108060006633 protein kinase Proteins 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 208000034578 Multiple myelomas Diseases 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 230000000505 pernicious effect Effects 0.000 description 8
- 239000000376 reactant Substances 0.000 description 8
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 8
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 8
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 7
- 101150012716 CDK1 gene Proteins 0.000 description 7
- 108010058546 Cyclin D1 Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 108010025020 Nerve Growth Factor Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000004992 fission Effects 0.000 description 7
- 230000002779 inactivation Effects 0.000 description 7
- 229940053128 nerve growth factor Drugs 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 7
- HRMBSWWTQBEJHL-UHFFFAOYSA-N 1-butylpiperidin-4-amine Chemical compound CCCCN1CCC(N)CC1 HRMBSWWTQBEJHL-UHFFFAOYSA-N 0.000 description 6
- VTNXQDWLEPTLMS-UHFFFAOYSA-N 1-chloropentan-1-amine Chemical compound CCCCC(N)Cl VTNXQDWLEPTLMS-UHFFFAOYSA-N 0.000 description 6
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 6
- IPIWUIYUXUVYDS-UHFFFAOYSA-N 2-cyclopentyl-7h-purine;dihydrochloride Chemical compound Cl.Cl.C1CCCC1C1=NC=C(NC=N2)C2=N1 IPIWUIYUXUVYDS-UHFFFAOYSA-N 0.000 description 6
- BZFKSWOGZQMOMO-UHFFFAOYSA-N 3-chloropropan-1-amine Chemical compound NCCCCl BZFKSWOGZQMOMO-UHFFFAOYSA-N 0.000 description 6
- BHEYXIGGNVYACW-UHFFFAOYSA-N 4-aminobutanoyl chloride Chemical compound NCCCC(Cl)=O BHEYXIGGNVYACW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- VESHMVJTPABQLX-UHFFFAOYSA-N CCClN Chemical compound CCClN VESHMVJTPABQLX-UHFFFAOYSA-N 0.000 description 6
- 108090000257 Cyclin E Proteins 0.000 description 6
- 102000003909 Cyclin E Human genes 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 6
- 229950010817 alvocidib Drugs 0.000 description 6
- 239000001273 butane Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 239000001294 propane Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 5
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 5
- 208000003200 Adenoma Diseases 0.000 description 5
- 206010001233 Adenoma benign Diseases 0.000 description 5
- 206010060999 Benign neoplasm Diseases 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 5
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 5
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 5
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 208000007766 Kaposi sarcoma Diseases 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 238000005804 alkylation reaction Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 201000004108 hypersplenism Diseases 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 5
- 206010028537 myelofibrosis Diseases 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- BCEKLYJIVXGPLQ-UHFFFAOYSA-N 1-(2-phenylethyl)piperidin-4-amine Chemical class C1CC(N)CCN1CCC1=CC=CC=C1 BCEKLYJIVXGPLQ-UHFFFAOYSA-N 0.000 description 4
- HIXAJGFVNMKLML-UHFFFAOYSA-N 1-(3-methoxypropyl)piperidin-4-amine Chemical class COCCCN1CCC(N)CC1 HIXAJGFVNMKLML-UHFFFAOYSA-N 0.000 description 4
- YFNAWWBCDBZGEJ-UHFFFAOYSA-N 1-(3-phenoxypropyl)piperidin-4-amine Chemical class C1CC(N)CCN1CCCOC1=CC=CC=C1 YFNAWWBCDBZGEJ-UHFFFAOYSA-N 0.000 description 4
- FMJGYAKKRNUHPQ-UHFFFAOYSA-N 1-(4-butoxybutyl)piperidin-4-amine Chemical class CCCCOCCCCN1CCC(N)CC1 FMJGYAKKRNUHPQ-UHFFFAOYSA-N 0.000 description 4
- JWLKITIAIKHSHG-UHFFFAOYSA-N 1-(4-phenylmethoxybutyl)piperidin-4-amine Chemical class C1CC(N)CCN1CCCCOCC1=CC=CC=C1 JWLKITIAIKHSHG-UHFFFAOYSA-N 0.000 description 4
- FHENXHUNMDAJMX-UHFFFAOYSA-N 1-(4-propoxybutyl)piperidin-4-amine Chemical class CCCOCCCCN1CCC(N)CC1 FHENXHUNMDAJMX-UHFFFAOYSA-N 0.000 description 4
- GKMFAUCQYCBJJQ-UHFFFAOYSA-N 1-(6-butoxyhexyl)piperidin-4-amine Chemical class CCCCOCCCCCCN1CCC(N)CC1 GKMFAUCQYCBJJQ-UHFFFAOYSA-N 0.000 description 4
- OXJRQRNSKJYRIE-UHFFFAOYSA-N 1-(6-phenylmethoxyhexyl)piperidin-4-amine Chemical class C1CC(N)CCN1CCCCCCOCC1=CC=CC=C1 OXJRQRNSKJYRIE-UHFFFAOYSA-N 0.000 description 4
- KOFALVUVVFTHMT-UHFFFAOYSA-N 1-(6-propoxyhexyl)piperidin-4-amine Chemical class CCCOCCCCCCN1CCC(N)CC1 KOFALVUVVFTHMT-UHFFFAOYSA-N 0.000 description 4
- MHKZEPLHUMBAES-UHFFFAOYSA-N 1-(pyridin-2-ylmethyl)piperidin-4-amine Chemical class C1CC(N)CCN1CC1=CC=CC=N1 MHKZEPLHUMBAES-UHFFFAOYSA-N 0.000 description 4
- MSXJQLZTWITCEC-UHFFFAOYSA-N 1-(pyridin-3-ylmethyl)piperidin-4-amine Chemical class C1CC(N)CCN1CC1=CC=CN=C1 MSXJQLZTWITCEC-UHFFFAOYSA-N 0.000 description 4
- XFBCPLXWYFVCTB-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)piperidin-4-amine Chemical class C1CC(N)CCN1CC1=CC=NC=C1 XFBCPLXWYFVCTB-UHFFFAOYSA-N 0.000 description 4
- WFONBGLNOUINIL-UHFFFAOYSA-N 1-[(2-methylphenyl)methyl]piperidin-4-amine Chemical class CC1=CC=CC=C1CN1CCC(N)CC1 WFONBGLNOUINIL-UHFFFAOYSA-N 0.000 description 4
- ZSNTXKRANYMRKW-UHFFFAOYSA-N 1-[(3-methoxyphenyl)methyl]piperidin-4-amine Chemical class COC1=CC=CC(CN2CCC(N)CC2)=C1 ZSNTXKRANYMRKW-UHFFFAOYSA-N 0.000 description 4
- JDACBLXRPFJSHT-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]piperidin-4-amine Chemical class C1=CC(OC)=CC=C1CN1CCC(N)CC1 JDACBLXRPFJSHT-UHFFFAOYSA-N 0.000 description 4
- BRUKSTGIAUDJQX-UHFFFAOYSA-N 1-[(4-methylphenyl)methyl]piperidin-4-amine Chemical class C1=CC(C)=CC=C1CN1CCC(N)CC1 BRUKSTGIAUDJQX-UHFFFAOYSA-N 0.000 description 4
- KHIYMQVQKBEXEZ-UHFFFAOYSA-N 1-[2-(benzenesulfinyl)ethyl]piperidin-4-amine Chemical class C1CC(N)CCN1CCS(=O)C1=CC=CC=C1 KHIYMQVQKBEXEZ-UHFFFAOYSA-N 0.000 description 4
- IONRLOMCVXWXIJ-UHFFFAOYSA-N 1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-amine Chemical class C1CC(N)CCN1CC1=CC=C(C(F)(F)F)C=C1 IONRLOMCVXWXIJ-UHFFFAOYSA-N 0.000 description 4
- QNCFUUKHWILSKF-UHFFFAOYSA-N 1-cyclopropyl-2-methylpiperidin-4-amine Chemical compound CC1CC(N)CCN1C1CC1 QNCFUUKHWILSKF-UHFFFAOYSA-N 0.000 description 4
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 4
- IXLYVDGIYOYCMO-UHFFFAOYSA-N 3-(4-aminopiperidin-1-yl)propan-1-ol Chemical class NC1CCN(CCCO)CC1 IXLYVDGIYOYCMO-UHFFFAOYSA-N 0.000 description 4
- UIMYLUZKHPRKEE-UHFFFAOYSA-N 4-(4-aminopiperidin-1-yl)butan-1-ol Chemical class NC1CCN(CCCCO)CC1 UIMYLUZKHPRKEE-UHFFFAOYSA-N 0.000 description 4
- MTWYGODGCZPZAU-UHFFFAOYSA-N 6-(4-aminopiperidin-1-yl)hexan-1-ol Chemical class NC1CCN(CCCCCCO)CC1 MTWYGODGCZPZAU-UHFFFAOYSA-N 0.000 description 4
- 206010000830 Acute leukaemia Diseases 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 description 4
- OEOFDSLYYWRCHR-UHFFFAOYSA-N COC(CN1CCC(CC1)N)S(=O)(=O)O Chemical class COC(CN1CCC(CC1)N)S(=O)(=O)O OEOFDSLYYWRCHR-UHFFFAOYSA-N 0.000 description 4
- 206010007275 Carcinoid tumour Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 108010068192 Cyclin A Proteins 0.000 description 4
- 102000002554 Cyclin A Human genes 0.000 description 4
- 102000003910 Cyclin D Human genes 0.000 description 4
- 108090000259 Cyclin D Proteins 0.000 description 4
- 102100036883 Cyclin-H Human genes 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 4
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 4
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 4
- 102000006835 Lamins Human genes 0.000 description 4
- 108010047294 Lamins Proteins 0.000 description 4
- 208000037062 Polyps Diseases 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 4
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 208000002458 carcinoid tumor Diseases 0.000 description 4
- 101150073031 cdk2 gene Proteins 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 4
- NXPIXCPSDPVJFT-UHFFFAOYSA-N ethyl 4-(4-aminopiperidin-1-yl)butanoate Chemical class CCOC(=O)CCCN1CCC(N)CC1 NXPIXCPSDPVJFT-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000005053 lamin Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000003961 neuronal insult Effects 0.000 description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
- 210000004180 plasmocyte Anatomy 0.000 description 4
- 208000037244 polycythemia vera Diseases 0.000 description 4
- 229960004839 potassium iodide Drugs 0.000 description 4
- 235000007715 potassium iodide Nutrition 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 230000002889 sympathetic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- MGTFEKWKCLDVNN-YPMHNXCESA-N (3r,4s)-1-benzyl-3-methylpiperidin-4-amine Chemical compound C1C[C@H](N)[C@H](C)CN1CC1=CC=CC=C1 MGTFEKWKCLDVNN-YPMHNXCESA-N 0.000 description 3
- HRQIDUFZNZJPDC-UHFFFAOYSA-N 1-(3-hydroxypropyl)piperidin-4-one Chemical compound OCCCN1CCC(=O)CC1 HRQIDUFZNZJPDC-UHFFFAOYSA-N 0.000 description 3
- QFWBXLYVHOMANN-UHFFFAOYSA-N 1-(3-methoxypropyl)piperidin-4-one Chemical compound COCCCN1CCC(=O)CC1 QFWBXLYVHOMANN-UHFFFAOYSA-N 0.000 description 3
- WLACLDJOIJWNRE-UHFFFAOYSA-N 1-(3-phenoxypropyl)piperidin-4-one Chemical compound C1CC(=O)CCN1CCCOC1=CC=CC=C1 WLACLDJOIJWNRE-UHFFFAOYSA-N 0.000 description 3
- WZQNXRRWXFORAM-UHFFFAOYSA-N 1-(4-hydroxybutyl)piperidin-4-one Chemical compound OCCCCN1CCC(=O)CC1 WZQNXRRWXFORAM-UHFFFAOYSA-N 0.000 description 3
- LGHVUCBQZNHVMG-UHFFFAOYSA-N 1-(4-phenylmethoxybutyl)piperidin-4-one Chemical compound C1CC(=O)CCN1CCCCOCC1=CC=CC=C1 LGHVUCBQZNHVMG-UHFFFAOYSA-N 0.000 description 3
- MHYZBPFYHPTPBZ-UHFFFAOYSA-N 1-(4-propoxybutyl)piperidin-4-one Chemical compound CCCOCCCCN1CCC(=O)CC1 MHYZBPFYHPTPBZ-UHFFFAOYSA-N 0.000 description 3
- HDMDRVMAFWMARH-UHFFFAOYSA-N 1-(6-butoxyhexyl)piperidin-4-one Chemical compound CCCCOCCCCCCN1CCC(=O)CC1 HDMDRVMAFWMARH-UHFFFAOYSA-N 0.000 description 3
- VJXNODUPFUUSQQ-UHFFFAOYSA-N 1-(6-phenylmethoxyhexyl)piperidin-4-one Chemical compound C1CC(=O)CCN1CCCCCCOCC1=CC=CC=C1 VJXNODUPFUUSQQ-UHFFFAOYSA-N 0.000 description 3
- TYJSENRQCFRZLY-UHFFFAOYSA-N 1-(6-propoxyhexyl)piperidin-4-one Chemical compound CCCOCCCCCCN1CCC(=O)CC1 TYJSENRQCFRZLY-UHFFFAOYSA-N 0.000 description 3
- WEGGUCATBXAQDP-UHFFFAOYSA-N 1-(cyclopropylmethyl)piperidin-4-one Chemical compound C1CC(=O)CCN1CC1CC1 WEGGUCATBXAQDP-UHFFFAOYSA-N 0.000 description 3
- JKWQJPKVFRHUDD-UHFFFAOYSA-N 1-[(3-methoxyphenyl)methyl]piperidin-4-one Chemical compound COC1=CC=CC(CN2CCC(=O)CC2)=C1 JKWQJPKVFRHUDD-UHFFFAOYSA-N 0.000 description 3
- ALUMNZBTDKQKNP-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]piperidin-4-one Chemical compound C1=CC(OC)=CC=C1CN1CCC(=O)CC1 ALUMNZBTDKQKNP-UHFFFAOYSA-N 0.000 description 3
- UPDPNZZCSVNONB-UHFFFAOYSA-N 1-[2-(benzenesulfinyl)ethyl]piperidin-4-one Chemical compound C1CC(=O)CCN1CCS(=O)C1=CC=CC=C1 UPDPNZZCSVNONB-UHFFFAOYSA-N 0.000 description 3
- WMRLJCRSLKALNT-UHFFFAOYSA-N 1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-one Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CCC(=O)CC1 WMRLJCRSLKALNT-UHFFFAOYSA-N 0.000 description 3
- OCNWYKFGWLGNHZ-UHFFFAOYSA-N 1-butylpiperidin-4-one Chemical compound CCCCN1CCC(=O)CC1 OCNWYKFGWLGNHZ-UHFFFAOYSA-N 0.000 description 3
- WRHMXXBHPIGXDS-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-(2-methoxyethyl)purin-6-amine Chemical compound C1=NC=2C(NCCOC)=NC(Cl)=NC=2N1C1CCCC1 WRHMXXBHPIGXDS-UHFFFAOYSA-N 0.000 description 3
- TWXYESHVTPLCIT-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-(3-fluorophenyl)purin-6-amine Chemical compound FC1=CC=CC(NC=2C=3N=CN(C=3N=C(Cl)N=2)C2CCCC2)=C1 TWXYESHVTPLCIT-UHFFFAOYSA-N 0.000 description 3
- MOXHLRBWXLUKEQ-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-(3-methoxypropyl)purin-6-amine Chemical compound C1=NC=2C(NCCCOC)=NC(Cl)=NC=2N1C1CCCC1 MOXHLRBWXLUKEQ-UHFFFAOYSA-N 0.000 description 3
- FRTFGHBJQQBKDS-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-[(3,4,5-trimethoxyphenyl)methyl]purin-6-amine Chemical compound COC1=C(OC)C(OC)=CC(CNC=2C=3N=CN(C=3N=C(Cl)N=2)C2CCCC2)=C1 FRTFGHBJQQBKDS-UHFFFAOYSA-N 0.000 description 3
- KQXMKGKYVRTADB-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-dodecylpurin-6-amine Chemical compound C1=NC=2C(NCCCCCCCCCCCC)=NC(Cl)=NC=2N1C1CCCC1 KQXMKGKYVRTADB-UHFFFAOYSA-N 0.000 description 3
- SOPSCIZOUSIZBH-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-phenylpurin-6-amine Chemical compound C=12N=CN(C3CCCC3)C2=NC(Cl)=NC=1NC1=CC=CC=C1 SOPSCIZOUSIZBH-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 208000005243 Chondrosarcoma Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 241000294743 Gamochaeta Species 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 101000980932 Homo sapiens Cyclin-dependent kinase inhibitor 2A Proteins 0.000 description 3
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 3
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 108060008487 Myosin Proteins 0.000 description 3
- 102000003505 Myosin Human genes 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000006288 Transcription Factor TFIIH Human genes 0.000 description 3
- 108010083256 Transcription Factor TFIIH Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- 208000017733 acquired polycythemia vera Diseases 0.000 description 3
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000003792 cranial nerve Anatomy 0.000 description 3
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 3
- VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 description 3
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000030609 dephosphorylation Effects 0.000 description 3
- 238000006209 dephosphorylation reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 201000003914 endometrial carcinoma Diseases 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 3
- 201000000564 macroglobulinemia Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000479 mitotic spindle apparatus Anatomy 0.000 description 3
- YDJXNYNKKXZBMP-UHFFFAOYSA-N n-phenethyl-4-piperidinone Chemical compound C1CC(=O)CCN1CCC1=CC=CC=C1 YDJXNYNKKXZBMP-UHFFFAOYSA-N 0.000 description 3
- 210000003739 neck Anatomy 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 230000001053 orthosympathetic effect Effects 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 150000004040 pyrrolidinones Chemical class 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- LVMPWFJVYMXSNY-UHFFFAOYSA-N (2,3-dimethoxyphenyl)methanamine Chemical compound COC1=CC=CC(CN)=C1OC LVMPWFJVYMXSNY-UHFFFAOYSA-N 0.000 description 2
- DIVNUTGTTIRPQA-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1OC DIVNUTGTTIRPQA-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- PPNRREMIPBRCCD-UHFFFAOYSA-N 1-(3-chloropropoxy)butane Chemical compound CCCCOCCCCl PPNRREMIPBRCCD-UHFFFAOYSA-N 0.000 description 2
- ZGQCIBPYNCHGCP-UHFFFAOYSA-N 1-(4-butoxybutyl)piperidin-4-one Chemical compound CCCCOCCCCN1CCC(=O)CC1 ZGQCIBPYNCHGCP-UHFFFAOYSA-N 0.000 description 2
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 2
- BOGOOJPPIZYGKN-UHFFFAOYSA-N 1-(6-hydroxyhexyl)piperidin-4-one Chemical compound OCCCCCCN1CCC(=O)CC1 BOGOOJPPIZYGKN-UHFFFAOYSA-N 0.000 description 2
- VQRBXYBBGHOGFT-UHFFFAOYSA-N 1-(chloromethyl)-2-methylbenzene Chemical compound CC1=CC=CC=C1CCl VQRBXYBBGHOGFT-UHFFFAOYSA-N 0.000 description 2
- VGISFWWEOGVMED-UHFFFAOYSA-N 1-(chloromethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CCl)=C1 VGISFWWEOGVMED-UHFFFAOYSA-N 0.000 description 2
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 2
- DMHZDOTYAVHSEH-UHFFFAOYSA-N 1-(chloromethyl)-4-methylbenzene Chemical compound CC1=CC=C(CCl)C=C1 DMHZDOTYAVHSEH-UHFFFAOYSA-N 0.000 description 2
- LQHWXULWFQQUDQ-UHFFFAOYSA-N 1-(pyridin-2-ylmethyl)piperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=N1 LQHWXULWFQQUDQ-UHFFFAOYSA-N 0.000 description 2
- OTULPMPRCARKLQ-UHFFFAOYSA-N 1-(pyridin-3-ylmethyl)piperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CN=C1 OTULPMPRCARKLQ-UHFFFAOYSA-N 0.000 description 2
- HGXOGFPPULJEEV-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)piperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=NC=C1 HGXOGFPPULJEEV-UHFFFAOYSA-N 0.000 description 2
- LHFRVPBWVSGTJQ-UHFFFAOYSA-N 1-[(2-methylphenyl)methyl]piperidin-4-one Chemical compound CC1=CC=CC=C1CN1CCC(=O)CC1 LHFRVPBWVSGTJQ-UHFFFAOYSA-N 0.000 description 2
- HCANSJOGHLDHGO-UHFFFAOYSA-N 1-[(4-methylphenyl)methyl]piperidin-4-one Chemical compound C1=CC(C)=CC=C1CN1CCC(=O)CC1 HCANSJOGHLDHGO-UHFFFAOYSA-N 0.000 description 2
- IJEMZYKPFZPVAV-UHFFFAOYSA-N 1-butoxy-4-chlorobutane Chemical compound CCCCOCCCCCl IJEMZYKPFZPVAV-UHFFFAOYSA-N 0.000 description 2
- SGHIMQQOVLREDP-UHFFFAOYSA-N 1-butoxy-5-chloropentane Chemical compound CCCCOCCCCCCl SGHIMQQOVLREDP-UHFFFAOYSA-N 0.000 description 2
- HFWTYUJKYNJKSA-UHFFFAOYSA-N 1-butoxy-6-chlorohexane Chemical compound CCCCOCCCCCCCl HFWTYUJKYNJKSA-UHFFFAOYSA-N 0.000 description 2
- DMXVTLBNHNYDEG-UHFFFAOYSA-N 1-chloro-1-(1-chloroheptoxy)heptane Chemical compound C(CCCCC)C(Cl)OC(CCCCCC)Cl DMXVTLBNHNYDEG-UHFFFAOYSA-N 0.000 description 2
- BASMANVIUSSIIM-UHFFFAOYSA-N 1-chloro-2-(chloromethyl)benzene Chemical compound ClCC1=CC=CC=C1Cl BASMANVIUSSIIM-UHFFFAOYSA-N 0.000 description 2
- YMDNODNLFSHHCV-UHFFFAOYSA-N 1-chloro-2-(diethylamino)ethane Natural products CCN(CC)CCCl YMDNODNLFSHHCV-UHFFFAOYSA-N 0.000 description 2
- DDGRAFHHXYIQQR-UHFFFAOYSA-N 1-chloro-3-(chloromethyl)benzene Chemical compound ClCC1=CC=CC(Cl)=C1 DDGRAFHHXYIQQR-UHFFFAOYSA-N 0.000 description 2
- BQLHMMQUVJCTAN-UHFFFAOYSA-N 1-chloro-3-methoxypropane Chemical compound COCCCCl BQLHMMQUVJCTAN-UHFFFAOYSA-N 0.000 description 2
- QODHJTGZDDJFDK-UHFFFAOYSA-N 1-chloro-3-propoxypropane Chemical compound CCCOCCCCl QODHJTGZDDJFDK-UHFFFAOYSA-N 0.000 description 2
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 2
- IXRDURXALZYREB-UHFFFAOYSA-N 1-chloro-4-ethoxybutane Chemical compound CCOCCCCCl IXRDURXALZYREB-UHFFFAOYSA-N 0.000 description 2
- KOFVMVKXNODFFN-UHFFFAOYSA-N 1-chloro-5-ethoxypentane Chemical compound CCOCCCCCCl KOFVMVKXNODFFN-UHFFFAOYSA-N 0.000 description 2
- IAHZEKJBFAHYAQ-UHFFFAOYSA-N 1-chloro-5-propoxypentane Chemical compound CCCOCCCCCCl IAHZEKJBFAHYAQ-UHFFFAOYSA-N 0.000 description 2
- PKANGULRDBMYCF-UHFFFAOYSA-N 1-chloro-6-ethoxyhexane Chemical compound CCOCCCCCCCl PKANGULRDBMYCF-UHFFFAOYSA-N 0.000 description 2
- DSTSPCRSYYOZJY-UHFFFAOYSA-N 1-chloro-6-methoxyhexane Chemical compound COCCCCCCCl DSTSPCRSYYOZJY-UHFFFAOYSA-N 0.000 description 2
- RLOALSTWARFHBA-UHFFFAOYSA-N 1-chloro-6-propoxyhexane Chemical compound CCCOCCCCCCCl RLOALSTWARFHBA-UHFFFAOYSA-N 0.000 description 2
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 2
- 125000006017 1-propenyl group Chemical group 0.000 description 2
- SNOFKGQEUYMNCE-UHFFFAOYSA-N 2,2,2-trifluoro-1-$l^{1}-oxidanylethanone Chemical compound [O]C(=O)C(F)(F)F SNOFKGQEUYMNCE-UHFFFAOYSA-N 0.000 description 2
- LECMBPWEOVZHKN-UHFFFAOYSA-N 2-(2-chloroethoxy)ethanol Chemical compound OCCOCCCl LECMBPWEOVZHKN-UHFFFAOYSA-N 0.000 description 2
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 2
- MNNZINNZIQVULG-UHFFFAOYSA-N 2-chloroethylbenzene Chemical compound ClCCC1=CC=CC=C1 MNNZINNZIQVULG-UHFFFAOYSA-N 0.000 description 2
- XNUCQTSEDXYZCQ-UHFFFAOYSA-N 2-chloroethylsulfinylbenzene Chemical compound ClCCS(=O)C1=CC=CC=C1 XNUCQTSEDXYZCQ-UHFFFAOYSA-N 0.000 description 2
- WJAVYWPXOXAOBS-UHFFFAOYSA-N 2-fluoro-1,4-dimethylbenzene Chemical compound CC1=CC=C(C)C(F)=C1 WJAVYWPXOXAOBS-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- UZGLOGCJCWBBIV-UHFFFAOYSA-N 3-(chloromethyl)pyridin-1-ium;chloride Chemical compound Cl.ClCC1=CC=CN=C1 UZGLOGCJCWBBIV-UHFFFAOYSA-N 0.000 description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
- LAMUXTNQCICZQX-UHFFFAOYSA-N 3-chloropropan-1-ol Chemical compound OCCCCl LAMUXTNQCICZQX-UHFFFAOYSA-N 0.000 description 2
- AZXLOLRTEJEZHJ-UHFFFAOYSA-N 3-chloropropoxybenzene Chemical compound ClCCCOC1=CC=CC=C1 AZXLOLRTEJEZHJ-UHFFFAOYSA-N 0.000 description 2
- XYQPOKBAQDQMQP-UHFFFAOYSA-N 3-chloropropoxymethylbenzene Chemical compound ClCCCOCC1=CC=CC=C1 XYQPOKBAQDQMQP-UHFFFAOYSA-N 0.000 description 2
- ZDHKVKPZQKYREU-UHFFFAOYSA-N 4-(chloromethyl)pyridine;hydron;chloride Chemical compound Cl.ClCC1=CC=NC=C1 ZDHKVKPZQKYREU-UHFFFAOYSA-N 0.000 description 2
- HXHGULXINZUGJX-UHFFFAOYSA-N 4-chlorobutanol Chemical class OCCCCCl HXHGULXINZUGJX-UHFFFAOYSA-N 0.000 description 2
- VRAARYWXGUUQRR-UHFFFAOYSA-N 4-chlorobutoxymethylbenzene Chemical compound ClCCCCOCC1=CC=CC=C1 VRAARYWXGUUQRR-UHFFFAOYSA-N 0.000 description 2
- DCBJCKDOZLTTDW-UHFFFAOYSA-N 5-chloropentan-1-ol Chemical compound OCCCCCCl DCBJCKDOZLTTDW-UHFFFAOYSA-N 0.000 description 2
- NFKHVAANLLONKQ-UHFFFAOYSA-N 5-chloropentoxymethylbenzene Chemical compound ClCCCCCOCC1=CC=CC=C1 NFKHVAANLLONKQ-UHFFFAOYSA-N 0.000 description 2
- JTEJPPKMYBDEMY-UHFFFAOYSA-N 5-methoxytryptamine Chemical compound COC1=CC=C2NC=C(CCN)C2=C1 JTEJPPKMYBDEMY-UHFFFAOYSA-N 0.000 description 2
- JNTPTNNCGDAGEJ-UHFFFAOYSA-N 6-chlorohexan-1-ol Chemical compound OCCCCCCCl JNTPTNNCGDAGEJ-UHFFFAOYSA-N 0.000 description 2
- FKCKIIVAHDKILR-UHFFFAOYSA-N 6-chlorohexoxymethylbenzene Chemical compound ClCCCCCCOCC1=CC=CC=C1 FKCKIIVAHDKILR-UHFFFAOYSA-N 0.000 description 2
- OSDWBNJEKMUWAV-UHFFFAOYSA-N Allyl chloride Chemical group ClCC=C OSDWBNJEKMUWAV-UHFFFAOYSA-N 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- MUYJFQUEFDKERR-UHFFFAOYSA-N C1CC=C(C1)N2C=NC3=CN=C(N=C32)Cl Chemical compound C1CC=C(C1)N2C=NC3=CN=C(N=C32)Cl MUYJFQUEFDKERR-UHFFFAOYSA-N 0.000 description 2
- SYLMUAHSGWQBAP-UHFFFAOYSA-N COC(CN1CCC(=O)CC1)S(=O)(=O)O Chemical compound COC(CN1CCC(=O)CC1)S(=O)(=O)O SYLMUAHSGWQBAP-UHFFFAOYSA-N 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 2
- 230000007118 DNA alkylation Effects 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102400000921 Gastrin Human genes 0.000 description 2
- 108010052343 Gastrins Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- 108010040897 Microfilament Proteins Proteins 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000033014 Plasma cell tumor Diseases 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000005485 Thrombocytosis Diseases 0.000 description 2
- 201000003761 Vaginal carcinoma Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229960003272 asparaginase Drugs 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 102000028861 calmodulin binding Human genes 0.000 description 2
- 108091000084 calmodulin binding Proteins 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 101150059448 cdk7 gene Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ZVTQWXCKQTUVPY-UHFFFAOYSA-N chloromethylcyclopropane Chemical compound ClCC1CC1 ZVTQWXCKQTUVPY-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 108040000002 cyclin-dependent protein kinase activating kinase activity proteins Proteins 0.000 description 2
- NWZXFAYYQNFDCA-UHFFFAOYSA-N cyclopenten-1-ol Chemical compound OC1=CCCC1 NWZXFAYYQNFDCA-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- INTMMHZKGCDQGT-UHFFFAOYSA-N diethyldiazene Chemical compound CCN=NCC INTMMHZKGCDQGT-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000009261 endocrine therapy Methods 0.000 description 2
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- LKCQEXSVXYMJJF-UHFFFAOYSA-N ethyl 4-(4-oxopiperidin-1-yl)butanoate Chemical compound CCOC(=O)CCCN1CCC(=O)CC1 LKCQEXSVXYMJJF-UHFFFAOYSA-N 0.000 description 2
- 229960003750 ethyl chloride Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 206010016629 fibroma Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 208000025189 neoplasm of testis Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000002990 parathyroid gland Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 208000028591 pheochromocytoma Diseases 0.000 description 2
- 208000010626 plasma cell neoplasm Diseases 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 208000003476 primary myelofibrosis Diseases 0.000 description 2
- 239000000649 purine antagonist Substances 0.000 description 2
- 239000003790 pyrimidine antagonist Substances 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000009871 tenuigenin Substances 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- AFWRJOYNLMVZQO-GMFATLNBSA-N (1r,2r,4as,8as)-1-[(1e,3e)-5-hydroxy-3-methylpenta-1,3-dienyl]-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1h-naphthalen-2-ol Chemical compound CC1(C)CCC[C@]2(C)[C@@H](/C=C/C(=C/CO)/C)[C@](C)(O)CC[C@H]21 AFWRJOYNLMVZQO-GMFATLNBSA-N 0.000 description 1
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- IDTWYHVEGJBGPT-UHFFFAOYSA-N (2,6-dichlorophenyl)hydrazine Chemical compound NNC1=C(Cl)C=CC=C1Cl IDTWYHVEGJBGPT-UHFFFAOYSA-N 0.000 description 1
- XEKGMBAKVJAVAZ-UHFFFAOYSA-N (2,6-dimethoxyphenyl)methanamine Chemical compound COC1=CC=CC(OC)=C1CN XEKGMBAKVJAVAZ-UHFFFAOYSA-N 0.000 description 1
- GHGPIPTUDQZJJS-UHFFFAOYSA-N (2-chlorophenyl)hydrazine Chemical compound NNC1=CC=CC=C1Cl GHGPIPTUDQZJJS-UHFFFAOYSA-N 0.000 description 1
- PENWGQNPFRRVQI-UHFFFAOYSA-N (2-fluorophenyl)hydrazine Chemical compound NNC1=CC=CC=C1F PENWGQNPFRRVQI-UHFFFAOYSA-N 0.000 description 1
- PXJACNDVRNAFHD-UHFFFAOYSA-N (2-methoxyphenyl)methanamine Chemical compound COC1=CC=CC=C1CN PXJACNDVRNAFHD-UHFFFAOYSA-N 0.000 description 1
- YUPUSBMJCFBHAP-UHFFFAOYSA-N (3,4,5-trimethoxyphenyl)methanamine Chemical compound COC1=CC(CN)=CC(OC)=C1OC YUPUSBMJCFBHAP-UHFFFAOYSA-N 0.000 description 1
- YGZJTYCCONJJGZ-UHFFFAOYSA-N (3,5-dimethoxyphenyl)methanamine Chemical compound COC1=CC(CN)=CC(OC)=C1 YGZJTYCCONJJGZ-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QADTUZQSGHZTNU-UHFFFAOYSA-N 1-(2-chloro-9-cyclopentylpurin-6-yl)-2-(2-chlorophenyl)hydrazine Chemical compound C=12N=CN(C3CCCC3)C2=NC(Cl)=NC=1NNC1=CC=CC=C1Cl QADTUZQSGHZTNU-UHFFFAOYSA-N 0.000 description 1
- MJJFYFIJGXGLID-UHFFFAOYSA-N 1-(3-butoxybutyl)piperidin-4-one Chemical compound CCCCOC(C)CCN1CCC(=O)CC1 MJJFYFIJGXGLID-UHFFFAOYSA-N 0.000 description 1
- MGTFEKWKCLDVNN-UHFFFAOYSA-N 1-benzyl-3-methylpiperidin-4-amine Chemical compound C1CC(N)C(C)CN1CC1=CC=CC=C1 MGTFEKWKCLDVNN-UHFFFAOYSA-N 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical group CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- GIAFURWZWWWBQT-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanol Chemical compound NCCOCCO GIAFURWZWWWBQT-UHFFFAOYSA-N 0.000 description 1
- SCLAOYDMJKOEAN-UHFFFAOYSA-N 2-[2-[(2-chloro-9-cyclopentylpurin-6-yl)amino]ethoxy]ethanol Chemical compound C1=NC=2C(NCCOCCO)=NC(Cl)=NC=2N1C1CCCC1 SCLAOYDMJKOEAN-UHFFFAOYSA-N 0.000 description 1
- JBMBVWROWJGFMG-UHFFFAOYSA-N 2-chloro-7h-purine Chemical compound ClC1=NC=C2NC=NC2=N1 JBMBVWROWJGFMG-UHFFFAOYSA-N 0.000 description 1
- CFTPMBWYBDKGSA-UHFFFAOYSA-N 2-cyclopentyl-7h-purine Chemical compound C1CCCC1C1=NC=C(NC=N2)C2=N1 CFTPMBWYBDKGSA-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
- PWGVOCGNHYMDLS-UHFFFAOYSA-N 3-(2-methoxyethoxy)propan-1-amine Chemical compound COCCOCCCN PWGVOCGNHYMDLS-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- FAXDZWQIWUSWJH-UHFFFAOYSA-N 3-methoxypropan-1-amine Chemical compound COCCCN FAXDZWQIWUSWJH-UHFFFAOYSA-N 0.000 description 1
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical group CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 1
- 150000004042 3-pyrrolidinones Chemical class 0.000 description 1
- XUJFOSLZQITUOI-UHFFFAOYSA-N 4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1 XUJFOSLZQITUOI-UHFFFAOYSA-N 0.000 description 1
- OGIQUQKNJJTLSZ-UHFFFAOYSA-N 4-butylaniline Chemical compound CCCCC1=CC=C(N)C=C1 OGIQUQKNJJTLSZ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940097276 5-methoxytryptamine Drugs 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- UZNQRSTWYFVQHM-UHFFFAOYSA-N 7H-purine trihydrochloride Chemical compound Cl.Cl.Cl.N1=CN=C2N=CNC2=C1 UZNQRSTWYFVQHM-UHFFFAOYSA-N 0.000 description 1
- KKZWBEZAZYTNNO-UHFFFAOYSA-N 9-cyclopentylpurine;dihydrochloride Chemical compound Cl.Cl.C1CCCC1N1C2=NC=NC=C2N=C1 KKZWBEZAZYTNNO-UHFFFAOYSA-N 0.000 description 1
- VRZWCYZJGUYTKU-UHFFFAOYSA-N 9-methylpurine Chemical compound N1=CN=C2N(C)C=NC2=C1 VRZWCYZJGUYTKU-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010043137 Actomyosin Proteins 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 description 1
- 208000003609 Bile Duct Adenoma Diseases 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- NPUXCLPWJUDMFG-UHFFFAOYSA-N C1CC=C(C1)C2=NC=C3C(=N2)N=C(N3)Cl Chemical compound C1CC=C(C1)C2=NC=C3C(=N2)N=C(N3)Cl NPUXCLPWJUDMFG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 101150053721 Cdk5 gene Proteins 0.000 description 1
- 101150090188 Cdk8 gene Proteins 0.000 description 1
- 206010008592 Cholangioadenoma Diseases 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000010126 Chondromatosis Diseases 0.000 description 1
- 208000019591 Chondromyxoid fibroma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 102000002428 Cyclin C Human genes 0.000 description 1
- 108010068155 Cyclin C Proteins 0.000 description 1
- 108010068237 Cyclin H Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000009512 Cyclin-Dependent Kinase Inhibitor p15 Human genes 0.000 description 1
- 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000007528 DNA Polymerase III Human genes 0.000 description 1
- 108010071146 DNA Polymerase III Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 1
- 208000001154 Dermoid Cyst Diseases 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000031206 Familial polycythaemia Diseases 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000980920 Homo sapiens Cyclin-dependent kinase 4 inhibitor D Proteins 0.000 description 1
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 1
- 101000713023 Homo sapiens G2/mitotic-specific cyclin-B2 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 230000027311 M phase Effects 0.000 description 1
- 101150078498 MYB gene Proteins 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 102000011961 Maturation-Promoting Factor Human genes 0.000 description 1
- 108010075942 Maturation-Promoting Factor Proteins 0.000 description 1
- 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
- 206010061298 Mucosal haemorrhage Diseases 0.000 description 1
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
- 101000983859 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Lipoprotein LpqH Proteins 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- VYVWRXOZPPPOTP-UHFFFAOYSA-N N1CCC(C(=O)N)CC1.N1CCC(CC1)NC(=O)N Chemical compound N1CCC(C(=O)N)CC1.N1CCC(CC1)NC(=O)N VYVWRXOZPPPOTP-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 241000212335 Perideridia gairdneri Species 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 208000007541 Preleukemia Diseases 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 206010056626 Pseudopolyp Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102100022151 Ragulator complex protein LAMTOR1 Human genes 0.000 description 1
- 241000773293 Rappaport Species 0.000 description 1
- 208000009527 Refractory anemia Diseases 0.000 description 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 101150112625 SSN3 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100150415 Schizosaccharomyces pombe (strain 972 / ATCC 24843) srb10 gene Proteins 0.000 description 1
- 101100368917 Schizosaccharomyces pombe (strain 972 / ATCC 24843) taz1 gene Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 206010040860 Skin haemorrhages Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 1
- 101000652566 Tetrahymena thermophila (strain SB210) Telomerase-associated protein of 19 kDa Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000002463 Transcription Factor TFIIIB Human genes 0.000 description 1
- 108010068071 Transcription Factor TFIIIB Proteins 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048211 Xanthelasma Diseases 0.000 description 1
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- WWDKVICMJWBJKJ-UHFFFAOYSA-N [4-(aminomethyl)cyclohexyl]methanol Chemical compound NCC1CCC(CO)CC1 WWDKVICMJWBJKJ-UHFFFAOYSA-N 0.000 description 1
- 208000019789 abdominal cramp Diseases 0.000 description 1
- 210000002187 accessory nerve Anatomy 0.000 description 1
- 210000004695 acinic cell Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 101150044616 araC gene Proteins 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 210000002947 bartholin's gland Anatomy 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- HRQGCQVOJVTVLU-UHFFFAOYSA-N bis(chloromethyl) ether Chemical compound ClCOCCl HRQGCQVOJVTVLU-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000021235 carbamoylation Effects 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical group [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003059 ependyma Anatomy 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 201000000497 familial melanoma Diseases 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- JISVIRFOSOKJIU-UHFFFAOYSA-N hexylidene Chemical group [CH2+]CCCC[CH-] JISVIRFOSOKJIU-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000054528 human CCNB2 Human genes 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 208000017819 hyperplastic polyp Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001501 megacaryocyte Anatomy 0.000 description 1
- 210000004175 meibomian gland Anatomy 0.000 description 1
- 210000003574 melanophore Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 201000003428 multiple mucosal neuroma Diseases 0.000 description 1
- 229940087004 mustargen Drugs 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- QOHMWDJIBGVPIF-UHFFFAOYSA-N n',n'-diethylpropane-1,3-diamine Chemical compound CCN(CC)CCCN QOHMWDJIBGVPIF-UHFFFAOYSA-N 0.000 description 1
- OCIDXARMXNJACB-UHFFFAOYSA-N n'-phenylethane-1,2-diamine Chemical compound NCCNC1=CC=CC=C1 OCIDXARMXNJACB-UHFFFAOYSA-N 0.000 description 1
- NVSYANRBXPURRQ-UHFFFAOYSA-N naphthalen-1-ylmethanamine Chemical compound C1=CC=C2C(CN)=CC=CC2=C1 NVSYANRBXPURRQ-UHFFFAOYSA-N 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- CMUOJBJRZUHRMU-UHFFFAOYSA-N nitrourea Chemical compound NC(=O)N[N+]([O-])=O CMUOJBJRZUHRMU-UHFFFAOYSA-N 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 208000003388 osteoid osteoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 108700042657 p16 Genes Proteins 0.000 description 1
- 101800002723 p18 Proteins 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- RFPMGSKVEAUNMZ-UHFFFAOYSA-N pentylidene Chemical group [CH2+]CCC[CH-] RFPMGSKVEAUNMZ-UHFFFAOYSA-N 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 208000022075 polyp of rectum Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 201000006870 primary polycythemia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- NGXSWUFDCSEIOO-UHFFFAOYSA-N pyrrolidin-3-amine Chemical compound NC1CCNC1 NGXSWUFDCSEIOO-UHFFFAOYSA-N 0.000 description 1
- QGKLPGKXAVVPOJ-UHFFFAOYSA-N pyrrolidin-3-one Chemical compound O=C1CCNC1 QGKLPGKXAVVPOJ-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 102200127349 rs11547328 Human genes 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 230000001573 trophoblastic effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (138)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3097598A | 1998-02-26 | 1998-02-26 | |
US13510998P | 1998-02-26 | 1998-02-26 | |
US09/030,975 | 1998-02-26 | ||
US09/247,053 US6479487B1 (en) | 1998-02-26 | 1999-02-09 | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1292789A CN1292789A (zh) | 2001-04-25 |
CN1143858C true CN1143858C (zh) | 2004-03-31 |
Family
ID=27363758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998033979A Expired - Fee Related CN1143858C (zh) | 1998-02-26 | 1999-02-18 | 6,9-二取代的2-[反-(氨基环己基)氨基]嘌呤,其组合物和用途 |
Country Status (17)
Country | Link |
---|---|
US (1) | US6479487B1 (zh) |
EP (1) | EP1056744B1 (zh) |
JP (1) | JP2002504552A (zh) |
CN (1) | CN1143858C (zh) |
AP (1) | AP1054A (zh) |
AU (1) | AU747151B2 (zh) |
BR (1) | BR9909256A (zh) |
CA (1) | CA2320474C (zh) |
EE (1) | EE04815B1 (zh) |
HU (1) | HUP0100889A3 (zh) |
IL (1) | IL138043A0 (zh) |
NO (1) | NO328509B1 (zh) |
PL (1) | PL194174B1 (zh) |
SK (1) | SK12902000A3 (zh) |
TR (1) | TR200002463T2 (zh) |
WO (1) | WO1999043675A1 (zh) |
ZA (1) | ZA991551B (zh) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6642231B2 (en) * | 1998-02-26 | 2003-11-04 | Aventis Pharmaceuticals Inc. | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
GB9903762D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
US6969720B2 (en) | 1999-03-17 | 2005-11-29 | Amr Technology, Inc. | Biaryl substituted purine derivatives as potent antiproliferative agents |
US6627633B2 (en) * | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
FR2793794B1 (fr) * | 1999-05-21 | 2001-07-27 | Hoechst Marion Roussel Inc | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
ATE322494T1 (de) * | 2000-01-07 | 2006-04-15 | Universitaire Instelling Antwe | Purin derivate, ihre herstellung und verwendung |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
FR2806626B1 (fr) * | 2000-03-22 | 2003-11-28 | Centre Nat Rech Scient | Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues |
MXPA02010222A (es) | 2000-04-18 | 2003-05-23 | Agouron Pharma | Pirazoles para inhibir proteina cinasa. |
EP1307462A2 (en) | 2000-08-09 | 2003-05-07 | Agouron Pharmaceuticals, Inc. | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
WO2002016326A1 (en) | 2000-08-18 | 2002-02-28 | Agouron Pharmaceuticals, Inc. | Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases |
GB0117075D0 (en) * | 2000-10-31 | 2001-09-05 | Aventis Pharm Prod Inc | Acyl and sulfonyl derivatives of 6, 9-distributed 2-(trans-1, 4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
US6861524B2 (en) * | 2000-10-31 | 2005-03-01 | Aventis Pharmaceuticals Inc. | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
DK1377579T3 (da) * | 2000-10-31 | 2009-08-31 | Aventis Pharma Inc | Acyl- og sulfonylderivater af 6,9-disubstitueret-2(trans-1,4-diaminocyklohexyl)puriner og deres anvendelse som antiproliferative midler |
FR2818642B1 (fr) * | 2000-12-26 | 2005-07-15 | Hoechst Marion Roussel Inc | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion |
US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
US6812232B2 (en) | 2001-09-11 | 2004-11-02 | Amr Technology, Inc. | Heterocycle substituted purine derivatives as potent antiproliferative agents |
US6667311B2 (en) * | 2001-09-11 | 2003-12-23 | Albany Molecular Research, Inc. | Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
ES2311755T3 (es) * | 2002-12-13 | 2009-02-16 | Smithkline Beecham Corporation | Compuestos de ciclohexilo como antagonistas de ccrs. |
US7211576B2 (en) | 2004-04-20 | 2007-05-01 | Hoffmann-La Roche Inc. | Diaminothiazoles |
KR100677396B1 (ko) * | 2004-11-20 | 2007-02-02 | 엘지전자 주식회사 | 음성인식장치의 음성구간 검출방법 |
BRPI1015135B1 (pt) | 2009-06-29 | 2021-08-03 | Incyte Holdings Corporation | Pirimidinonas inibidoras de pi3k, composição compreendendo tais compostos, bem como usos dos mesmos |
WO2011075643A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
AR079529A1 (es) * | 2009-12-18 | 2012-02-01 | Incyte Corp | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k |
EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
WO2012087881A1 (en) | 2010-12-20 | 2012-06-28 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
CN102295594B (zh) * | 2011-07-12 | 2016-01-20 | 上海医药工业研究院 | 4-n-取代-1-(3-甲氧基丙基)-4-哌啶胺类化合物及制备和应用 |
CN102898356B (zh) * | 2011-07-29 | 2015-08-26 | 上海医药工业研究院 | 1-(3-甲氧基丙基)-4-哌啶胺及其盐的制备方法 |
ES2722524T3 (es) | 2011-09-02 | 2019-08-13 | Incyte Holdings Corp | Heterociclaminas como inhibidores de pi3k |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
US20140199728A1 (en) | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
CN103193699B (zh) * | 2013-04-18 | 2015-04-15 | 安徽赛诺医药化工有限公司 | 一种制备普卡必利中间体的新方法 |
CN103508939A (zh) * | 2013-06-30 | 2014-01-15 | 北京万全德众医药生物技术有限公司 | 一种制备普卡必利中间体1-(3-甲氧基丙基)-4-哌啶胺的方法 |
CN103848777B (zh) * | 2014-03-18 | 2016-04-13 | 悦康药业集团有限公司 | 一种n-(3-甲氧基丙基)-4-氨基哌啶的合成方法 |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
MD3831833T2 (ro) | 2015-02-27 | 2023-04-30 | Incyte Holdings Corp | Procedee pentru prepararea unui inhibitor PI3K |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
HUE061989T2 (hu) | 2016-03-16 | 2023-09-28 | Kura Oncology Inc | Szubsztituált tieno[2,3-D]pirimidin származékok mint menin-MLL inhibitorai és alkalmazási eljárások |
MX2018011092A (es) | 2016-03-16 | 2018-11-22 | Kura Oncology Inc | Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso. |
CZ308029B6 (cs) * | 2017-03-20 | 2019-11-06 | Univerzita PalackĂ©ho v Olomouci | 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky |
CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
MX2023013173A (es) | 2021-05-07 | 2023-11-30 | Kymera Therapeutics Inc | Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos. |
CN115677567A (zh) * | 2022-11-15 | 2023-02-03 | 大唐环境产业集团股份有限公司 | 一种4-氨基-1-哌啶丙醇的合成方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4232155A (en) | 1979-09-13 | 1980-11-04 | Bristol-Myers Company | Purine compounds |
ATE219519T1 (de) * | 1989-01-23 | 2002-07-15 | Chiron Corp | Rekombinanttherapien für infektionen und hyperproliferative störungen |
AU658698B2 (en) | 1991-12-06 | 1995-04-27 | Aventis Pharmaceuticals Inc. | Novel trans cyclopentanyl purine analogs useful as immunosuppressants |
US5516631A (en) * | 1992-10-13 | 1996-05-14 | La Jolla Cancer Research Foundation | Method of inhibiting replication of hyperproliferative cells |
GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
US5688665A (en) * | 1994-01-07 | 1997-11-18 | Fred Hutchinson Cancer Research Center | Isolated nucleic acid molecules encoding the p27 KIP-1 protein |
GB9414208D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
CA2234609C (en) | 1995-11-01 | 2006-11-28 | Novartis Ag | 2-amino-6-anilino-purine derivatives and processes for their preparation |
FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
US5866702A (en) | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
CA2297967A1 (en) | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
MXPA01007851A (es) | 1999-02-01 | 2003-06-04 | Cv Therapeutics Inc | Inhibidores purina de cinasa 2 e 1kb-alfa dependientes del ciclin. |
FR2793794B1 (fr) * | 1999-05-21 | 2001-07-27 | Hoechst Marion Roussel Inc | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
-
1999
- 1999-02-09 US US09/247,053 patent/US6479487B1/en not_active Expired - Fee Related
- 1999-02-18 EP EP99908220A patent/EP1056744B1/en not_active Expired - Lifetime
- 1999-02-18 PL PL99342604A patent/PL194174B1/pl not_active IP Right Cessation
- 1999-02-18 JP JP2000533430A patent/JP2002504552A/ja active Pending
- 1999-02-18 IL IL13804399A patent/IL138043A0/xx not_active IP Right Cessation
- 1999-02-18 CA CA002320474A patent/CA2320474C/en not_active Expired - Fee Related
- 1999-02-18 EE EEP200000489A patent/EE04815B1/xx not_active IP Right Cessation
- 1999-02-18 CN CNB998033979A patent/CN1143858C/zh not_active Expired - Fee Related
- 1999-02-18 TR TR2000/02463T patent/TR200002463T2/xx unknown
- 1999-02-18 WO PCT/US1999/003450 patent/WO1999043675A1/en active IP Right Grant
- 1999-02-18 BR BR9909256-5A patent/BR9909256A/pt not_active Application Discontinuation
- 1999-02-18 AP APAP/P/2000/001922A patent/AP1054A/en active
- 1999-02-18 SK SK1290-2000A patent/SK12902000A3/sk unknown
- 1999-02-18 AU AU27709/99A patent/AU747151B2/en not_active Ceased
- 1999-02-18 HU HU0100889A patent/HUP0100889A3/hu unknown
- 1999-02-25 ZA ZA9901551A patent/ZA991551B/xx unknown
-
2000
- 2000-08-25 NO NO20004280A patent/NO328509B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EE04815B1 (et) | 2007-04-16 |
IL138043A0 (en) | 2001-10-31 |
NO20004280D0 (no) | 2000-08-25 |
SK12902000A3 (sk) | 2001-04-09 |
EP1056744A1 (en) | 2000-12-06 |
CA2320474C (en) | 2005-05-10 |
EP1056744B1 (en) | 2003-10-22 |
ZA991551B (en) | 1999-08-26 |
US6479487B1 (en) | 2002-11-12 |
AU747151B2 (en) | 2002-05-09 |
NO20004280L (no) | 2000-10-25 |
PL194174B1 (pl) | 2007-05-31 |
WO1999043675A1 (en) | 1999-09-02 |
CN1292789A (zh) | 2001-04-25 |
AU2770999A (en) | 1999-09-15 |
EE200000489A (et) | 2002-04-15 |
TR200002463T2 (tr) | 2000-12-21 |
AP1054A (en) | 2002-04-01 |
NO328509B1 (no) | 2010-03-08 |
JP2002504552A (ja) | 2002-02-12 |
BR9909256A (pt) | 2000-11-28 |
HUP0100889A2 (hu) | 2002-01-28 |
CA2320474A1 (en) | 1999-09-02 |
PL342604A1 (en) | 2001-06-18 |
HUP0100889A3 (en) | 2003-07-28 |
AP2000001922A0 (en) | 2000-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1143858C (zh) | 6,9-二取代的2-[反-(氨基环己基)氨基]嘌呤,其组合物和用途 | |
CN1128149C (zh) | 6,9-二取代的2-[反-(4-氨基环己基)氨基]嘌呤 | |
CN1273466C (zh) | 具有唑基的喹啉衍生物和喹唑啉衍生物 | |
CN1227249C (zh) | 嘧啶化合物 | |
CN1138778C (zh) | 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途 | |
CN1211373C (zh) | 用作抗肿瘤药的2,4-二(杂-)芳基氨基(-氧基)-5-取代的嘧啶 | |
CN1269813C (zh) | 作为细胞增生抑制剂的咪唑-5-基-2-苯胺基-嘧啶 | |
CN1142919C (zh) | 作为抗肿瘤剂的喹唑啉衍生物 | |
CN101031559A (zh) | 氨基环脲衍生物和其制法及作为激酶抑制剂的医药用途 | |
CN101031569A (zh) | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 | |
CN1788001A (zh) | 可用于治疗赘生性疾病、炎性和免疫系统病症的2,4-二(苯氨基)嘧啶 | |
CN1633419A (zh) | Cdk抑制性嘧啶化合物、其制备方法以及作为药物的应用 | |
CN1675225A (zh) | 大环嘧啶化合物、其制备方法以及作为药物的应用 | |
CN1867553A (zh) | 作为cdk 和/或vegf 抑制剂的氨基亚砜取代的嘧啶化合物、其制备方法以及作为药物的用途 | |
CN1067988C (zh) | 吲哚酰基胍衍生物 | |
CN1606444A (zh) | 人磷脂酰肌醇3-激酶δ抑制剂 | |
CN1350528A (zh) | 作为抗肿瘤剂的4,5,6,7-四氢吲唑衍生物 | |
CN1788000A (zh) | 酞嗪酮衍生物 | |
CN1882580A (zh) | 作为抗增殖药物的喹唑啉衍生物 | |
CN1597667A (zh) | 用作血管生成抑制剂的喹唑啉衍生物 | |
CN1703405A (zh) | 用作糖原合酶激酶3β抑制剂的氨基苯甲酰胺衍生物 | |
CN1319133A (zh) | 选择性地调节蛋白激酶活性的短肽 | |
CN1542010A (zh) | 吡咯并三嗪和嘧啶化合物 | |
CN1993356A (zh) | 作为组蛋白脱乙酰基酶新颖抑制剂的取代丙烯基哌嗪衍生物 | |
CN1094043A (zh) | 喹唑啉衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: AVENTIS SAAB CO., LTD. Free format text: FORMER OWNER: AVENTIS HOLDINGS INC. Effective date: 20100928 Owner name: AVENTIS HOLDINGS INC. Free format text: FORMER OWNER: HMR PHARMACEUTICAL CO., LTD. Effective date: 20100928 Owner name: HMR PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: AWANDIS PHARMACEUTICAL CORP. Effective date: 20100928 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20100928 Address after: Delaware Patentee after: Aventis Holdings, Inc. Address before: Delaware Patentee before: Avant Holdings Effective date of registration: 20100928 Address after: Delaware Patentee after: Avant Holdings Address before: Delaware Patentee before: HMR Pharmaceutical Co. Effective date of registration: 20100928 Address after: Delaware Patentee after: HMR Pharmaceutical Co. Address before: New jersey, USA Patentee before: AVENTIS PHARMACEUTICALS Inc. |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040331 Termination date: 20120218 |